1. In Vivo
  2. >>Business Strategy

Quest Diagnostics' Turnaround Challenge

Quest Diagnostics was born into the troubled world of reference laboratories. It is cleaning house internally. But its bigger hurdle, one facing all reference laboratories, may be creating a viable role for itself in a world dominated by new customers with different needs.

It's been a rough year for reference laboratories. Several larger ones-including Physicians Clinical Laboratory Inc., and Meris Laboratories Inc.-are in Chapter 11 bankruptcy or close to it. Laboratory Corp. of America Holdings (LCA) can't meet interest payments on its debt and is undergoing a financial restructuring. The largest reference laboratories have all had recent management changes at their most senior levels. And relief doesn't appear to be in sight. The government continues its efforts to cut pricing and utilization of tests, and third-party pricing pressures remain, as competition from hospital laboratories and integrated delivery systems grows.

In the midst of this turmoil came the spin-off in January of Quest Diagnostics Inc. from Corning Inc. [See...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.